RecruitingPhase 2NCT06111885

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

99 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Kidney Stone

Summary

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Chlorthalidone 25mg, a drug called Hydrochlorothiazide 50Mg, and others for people with kidney stone. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.